StockNews.com Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX)

StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report published on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Price Performance

Tenax Therapeutics stock opened at $3.57 on Wednesday. The firm has a 50-day moving average of $3.72 and a two-hundred day moving average of $3.63. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.99) by $0.16. Equities analysts forecast that Tenax Therapeutics will post -6.68 EPS for the current fiscal year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.